Birzeit Pharmaceuticals Company

PLSE:BPC Stock Report

Market Cap: US$158.9m

Birzeit Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Birzeit Pharmaceuticals's earnings have been declining at an average annual rate of -12.4%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 4.8% per year. Birzeit Pharmaceuticals's return on equity is 3.6%, and it has net margins of 9.4%.

Key information

-12.4%

Earnings growth rate

-12.0%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate4.8%
Return on equity3.6%
Net Margin9.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Birzeit Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

PLSE:BPC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2438470
30 Jun 2440370
31 Mar 2442380
31 Dec 2343680
30 Sep 2344670
30 Jun 2345670
31 Mar 2345770
31 Dec 2247870
30 Sep 22471080
30 Jun 22481280
31 Mar 22501470
31 Dec 21451270
30 Sep 21431170
30 Jun 21401070
31 Mar 2135770
31 Dec 2036770
30 Sep 2035870
30 Jun 2035880
31 Mar 2035870
31 Dec 19351070
30 Sep 1933870
30 Jun 1932760
31 Mar 1935860
31 Dec 1836860
30 Sep 18351060
30 Jun 18341060
31 Mar 18331160
31 Dec 17331160
30 Sep 1734860
30 Jun 1734960
31 Mar 1734860
31 Dec 1632850
30 Sep 1630650
30 Jun 1628550
31 Mar 1628550
31 Dec 1526550
30 Sep 1527550
30 Jun 1527550
31 Mar 1526550
31 Dec 1425450
30 Sep 1425650
30 Jun 1425750
31 Mar 1426550
31 Dec 1325550

Quality Earnings: BPC has a large one-off loss of $2.3M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: BPC's current net profit margins (9.4%) are lower than last year (13.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BPC's earnings have declined by 12.4% per year over the past 5 years.

Accelerating Growth: BPC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BPC had negative earnings growth (-38.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (6.1%).


Return on Equity

High ROE: BPC's Return on Equity (3.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 20:23
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Birzeit Pharmaceuticals Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution